11 completed, 1 not yet recruiting, 1 unknown. 6 Phase 3, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 5, Unknown 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow AryoGen Pharmed Co.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational Study efmoroctocog alfa - Hemophilia A, Hemophilia | Not yet recruiting | AryoGen Pharmed Co. | 262 | 2026-08-23 | 2026-08-28 | |
| rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study Factor VIII, recombinant human with Fc fusion (rFVIII-Fc) - Severe Hemophilia A | Phase 3 | Completed | AryoGen Pharmed Co. | 50 | 2023-07-22 | 2023-11-18 |
| VedAryo® (Vedolizumab) Effectiveness and Safety Evaluation Vedolizumab - Ulcerative Colitis (UC), Crohn Disease (CD) | Completed | AryoGen Pharmed Co. | 150 | 2023-07-16 | 2025-12-10 | |
| Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors Eptacog alfa, activated - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Early Phase 1 | Completed | AryoGen Pharmed Co. | 14 | 2020-12-29 | 2022-09-10 |
| Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors Biosimilar eptacog alfa, activated (AryoSeven), Eptacog alfa, activated (Novoseven) - Hemophilia A or B With Inhibitor | Phase 3 | Completed | AryoGen Pharmed Co. | 48 | 2018-07-23 | 2021-02-04 |
| Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women Denosumab, calcium, vitamin D - Osteoporosis | Phase 3 | Unknown | AryoGen Pharmed Co. | 190 | 2017-04-29 | 2020-07-10 |
| Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency Eptacog alfa, biosimilar, Novoseven - Factor VII Deficiency | Phase 3 | Completed | AryoGen Pharmed Co. | 24 | 2017-03-01 | 2021-02-04 |
| AryoTrust® (Trastuzumab) Safety Study Trastuzumab - Breast Cancer | Completed | AryoGen Pharmed Co. | 597 | 2017-02-22 | 2023-10-31 | |
| Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects Etanercept - Phase 1, Bioequivalence | Phase 1 | Completed | AryoGen Pharmed Co. | 34 | 2016-12-04 | 2018-09-19 |
| Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer Bevacizumab + FOLFIRI-3 - Metastatic Colorectal Cancer | Phase 3 | Completed | AryoGen Pharmed Co. | 126 | 2016-10-04 | 2021-01-22 |
| Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide - Malignant Neoplasm of Breast | Phase 3 | Completed | AryoGen Pharmed Co. | 108 | 2016-07-09 | 2024-06-28 |
| Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Completed | AryoGen Pharmed Co. | 200 | 2016-06-13 | 2022-02-15 | |
| Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis Etanercept - Rheumatoid Arthritis, Ankylosing Spondylitis | Completed | AryoGen Pharmed Co. | 583 | 2014-04-04 | 2020-10-19 |
Hemophilia A (3) · Breast Neoplasms (2) · Factor VII Deficiency (2) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Colitis, Ulcerative (1) · Colorectal Neoplasms (1) · Crohn Disease (1) · Inflammatory Bowel Diseases (1) · Osteoporosis (1) · Spondylitis, Ankylosing (1) · Thrombasthenia (1)
Etanercept (2) · Factor VIII (2) · Trastuzumab (2) · recombinant FVIIa (2) · Bevacizumab (1) · Biosimilar Pharmaceuticals (1) · Calcium (1) · Cyclophosphamide (1) · Denosumab (1) · Docetaxel (1) · Factor VII (1) · Fluorouracil (1) · Leucovorin (1) · Vitamin D (1) · etanercept biosimilar SB4 (1)
Iran (13) · Turkey (Türkiye) (1)
Massimo Iacobelli, MD (3) · Ahmadreza Jamshidi (1) · Aziz Eghbali, Assoc. Prof. (1) · Fatemeh Homaee Shandiz, Prof. (1) · Hamid Rezvani, M.D (1) · Mohammad Faranoush, MD (1) · Reza Safaei, M.D (1)
PMID 23964932, PMID 32334845, PMID 33432540, PMID 35773713, PMID 38658485, PMID 39076099, PMID 39934428